Clinical trials: COVID-19 Induced Pneumonia
Anosmia, Hyposmia
Stellate Ganglion Block for COVID-19-Induced Olfactory Dysfunction
Chronic olfactory dysfunction from the COVID-19 pandemic is a growing public health crisis with up to 1.2 million people in the Unites States affected.
- Conditions
- Anosmia, Hyposmia, Parosmia, Olfactory Disorder
- Trial name
- NCT05445921
- Testing
- Stellate Ganglion Block
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Washington University School of Medicine
Anosmia, Ageusia
Efficacy of Photobiomodulation in the Rehabilitation of Olfactory Dysfunctions Induced by Long COVID-19
On January 30, 2020, the WHO (World Health Organization) declared the new coronavirus pandemic as the sixth public health emergency of international concern.
- Conditions
- Anosmia, Ageusia, COVID-19, Rehabilitation
- Trial name
- NCT06423495
- Testing
- low-intensity laser treatment
- Where
- Brazil
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Gaffree & Guinle Universitary Hospital
COVID-19, Respiratory Failure
Infusion of Prostacyclin (Iloprost) vs Placebo for 72-hours in COVID-19 Patients With Respiratory Failure
The purpose of this trial is to investigate the efficacy and safety of continuous intravenous administration of low dose iloprost versus placebo for 72-hours, in 80 patients with COVID-19 suffering from respiratory failure.
- Trial name
- COMBAT-COVID (NCT04420741)
- Testing
- Iloprost, Isotonic saline
- Where
- 5 sites in Denmark
- Volunteers
- 80 people
- Sponsor
- Pär Johansson
Covid19
Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Treatment of COVID-19 Acute Respiratory Distress
This is a Phase 2 study to assess COVI-MSC in the setting of current standard of care in hospitalized subjects with RT-PCR confirmed SARS-CoV-2 (COVID-19) infection and acute respiratory distress / acute respiratory distress…
- Trial name
- NCT04905836
- Testing
- COVI-MSC
- Where
- 6 sites in United States
- Volunteers
- 60 people
- Sponsor
- Sorrento Therapeutics, Inc.
Anxiety Depression, Alcohol Abuse
CBD Oil for Reducing Emotional Impact of COVID-19
Our purpose is to conduct a 4-arm placebo-controlled clinical trial to investigate the relative clinical efficacy of 300 mg. of pure hemp-derived CBD isolate, 300 mg. of full spectrum CBD oil, 300 mg.
- Conditions
- Anxiety Depression, Alcohol Abuse, Substance Abuse, Anger
- Trial name
- CBDOIL (NCT04603781)
- Testing
- CBD Isolate, Full Spectrum CBD Oil, Broad-Spectrum CBD Oil
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Texas at Austin
Covid19, Pneumonia
Intravenous Immunoglobulin (IVIG, Bioven) Efficacy Assess for COVID-19 / SARS-CoV-2 Severe Pneumonia Complex Treatment
Pneumonia caused by coronavirus infection COVID-19 is characterized by a combination of several dangerous factors that consistently worsen the patient's condition: viral lung damage early in the disease; a sharp increase in…
- Trial name
- NCT04500067
- Testing
- IVIG
- Where
- 9 sites in Ukraine
- Volunteers
- 76 people
- Sponsor
- Biopharma Plasma LLC
Covid-19, Sars-CoV2
Convalescent Plasma in ICU Patients With COVID-19-induced Respiratory Failure
This study will assess the feasibility of administering multiple doses of convalescent plasma (from people who have recovered form SARS-CoV-2) to Covid-19 positive patients in the Intensive Care Unit receiving mechanical…
- Trial name
- NCT04353206
- Testing
- Multiple Doses of Anti-SARS-CoV-2 convalescent plasma
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Noah Merin
COVID19, ARDS
REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumonia
To assess the safety and efficacy of CK0802 in treatment of patients with COVID-19 induced moderate-to-severe PNA-ARDS.
- Trial name
- RESOLVE (NCT04468971)
- Testing
- CK0802
- Where
- 5 sites in United States
- Volunteers
- 45 people
- Sponsor
- Cellenkos, Inc.
Covid19
Study of the Commercial Scale SARS-CoV-2 Vaccine Against the Pilot Scale Among Adults, and Bridging Study of the Immunogenicity in Elderly Against That in Adults
This study is a randomized, double-blinded clinical Trial, to evaluate the non-inferiority of the commercial scale Inactivated SARS-CoV-2 vaccine against that of the pilot scale among adults aged 26-45 years, and the…
- Trial name
- NCT04617483
- Testing
- Two doses of commercial scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14, Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14, Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14 in elderly
- Where
- China
- Volunteers
- 1,040 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
Covid-19, ARDS, Human
Nebulized Heparin for the Treatment of COVID-19 Induced Lung Injury
Randomized, placebo controlled study to determine if nebulized heparin may reduce the severity of lung injury caused by the novel coronavirus, also known as COVID-19
- Conditions
- Covid-19, ARDS, Human, Acute Lung Injury
- Trial name
- NCT04397510
- Testing
- Heparin, 0.9% Sodium-chloride
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Frederick Health
Acute Respiratory Distress Syndrome, Covid19
Safety of T Regulatory Cell Therapy in Subjects With COVID-19 Induced Acute Respiratory Distress Syndrome
This study is to evaluate the feasibility and safety of treatment with related donor Human Leukocyte Antigen (HLA) matched or haploidentical allogeneic T regulatory cells in patients with COVID 19 induced ARDS.
- Trial name
- NCT04737161
- Testing
- T regulatory cells
- Where
- United States
- Sponsor
- Stanford University
COVID-19, Mechanical Ventilation Pressure High
Different PEEP Settings of COVID-19 Induced ARDS
This was a multi-center prospective study. All consecutive severe cases of COVID-19 whose PO2/FiO2<300mmHg with invasive ventilation admitted to 5 fixed-point receive COVID-19 patients hospitals in Wuhan from 5 March to 15 March…
- Conditions
- COVID-19, Mechanical Ventilation Pressure High, Acute Respiratory Distress Syndrome
- Trial name
- NCT04359251
- Testing
- Gas exchanges at different PEEP, lung mechanics at different PEEP, Hemodynamics changes at different PEEP
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Southeast University, China
ARDS, Human, COVID
Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib in the treatment of patients with COVID-19 severe pneumonia.
- Trial name
- RuXoCoil (NCT04359290)
- Testing
- Ruxolitinib administration
- Where
- Germany
- Volunteers
- 15 people
- Sponsor
- Philipps University Marburg
CoronaVirus Induced Disease-2019 (COVID-19)
Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Lung failure is the main cause of death related to COVID-19 infection.
- Trial name
- iNSPIRE (NCT04375397)
- Testing
- Ibrutinib
- Where
- 9 sites in United States
- Volunteers
- 46 people
- Sponsor
- AbbVie
Alcoholic Liver Disease, COVID 19 Pneumonia
Study of HMB-enriched Amino Acid Supplementation in Patients With Alcoholic Liver Disease and COVID-19
Patients with COVID-19 and comorbidities including alcohol associated liver disease (ALD) are at risk for severe illness and abrupt or sudden clinical deterioration with ventilatory failure.
- Trial name
- NCT04858412
- Testing
- β-hydroxy β-methyl butyrate (HMB) enriched amino acid, Balanced amino acid
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- The Cleveland Clinic
COVID-19, Cancer
COVID EHR COHORT at the University of Wisconsin
This cohort study will obtain electronic health record (EHR) data (limited data set) from 21 health systems affiliated with the Cancer Center Cessation Initiative (C3I) network or health systems with large numbers of COVID-19…
- Conditions
- COVID-19, Cancer, Nicotine Dependence, Pulmonary Disease
- Trial name
- CEC-UW (NCT04506528)
- Where
- United States
- Volunteers
- 1,634,381 people
- Sponsor
- University of Wisconsin, Madison
Parosmia
Stellate Ganglion Block With Lidocaine for the Treatment of COVID-19-Induced Parosmia
Chronic olfactory dysfunction, both hyposmia and parosmia, from the COVID-19 pandemic is a growing public health crisis, affecting up to 1.2 million people in the United States.
- Trial name
- Stella (NCT06055270)
- Testing
- Stellate Ganglion Block
- Where
- Canada
- Volunteers
- 44 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
SARS-CoV-2 Infection
Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)
The mortality rate of the disease caused by the corona virus induced disease (COVID-19) has been estimated to be 3.7% (WHO), which is more than 10-fold higher than the mortality of influenza.
- Trial name
- CORON-ACT (NCT04335071)
- Testing
- Tocilizumab (TCZ)
- Where
- 4 sites in Switzerland
- Volunteers
- 5 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
COVID-19
Aerosol Combination Therapy of All-trans Retinoic Acid and Isotretinoin as A Novel Treatment for Inducing Neutralizing Antibodies in COVID -19 Infected Patients Better Than Vaccine : An Innovative Treatment
Aerosol Combination therapy of All-trans retinoic acid and Isotretinoin as A novel Treatment for Inducing Neutralizing Antibodies in COVID -19 Infected Patients better than vaccine : An innovative Treatment Mahmoud…
- Trial name
- Antibodies (NCT04396067)
- Testing
- Aerosolized 13 cis retinoic acid, Aerosolized All trans retinoic acid
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Kafrelsheikh University
Cytokine Release Syndrome (CRS) in Patients With COVID-19-induced Pneumonia
Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia
This was a multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of canakinumab plus standard-of-care (SOC) compared with placebo plus SOC in patients with COVID-19-induced pneumonia…
- Trial name
- CAN-COVID (NCT04362813)
- Testing
- Canakinumab
- Where
- 39 sites in United States, France and 4 more
- Volunteers
- 454 people
- Sponsor
- Novartis Pharmaceuticals